Skip to main content
. 2016 Sep 20;5(10):2977–2988. doi: 10.1002/cam4.866

Figure 6.

Figure 6

Effect of recombinant canstatin on the phosphorylation of vascular endothelial growth factor receptors (VEGFR)‐1 and ‐2 in rh vascular endothelial growth factor (VEGF)‐A‐treated HLMECs. (A) HLMECs were treated with different concentrations of recombinant canstatin (0, 0.5, 40 μg/mL) in the presence of 20 ng/mL of rhVEGF‐A. Cell lysates were immunoprecipitated with anti‐phospho‐Tyr (anti‐p‐Tyr) antibody. The presence of p‐VEGFR‐1 and p‐VEGFR‐2 in immunoprecipitates was detected via western blot analysis using anti‐VEGFR‐1 and anti‐VEGFR‐2 antibodies. (B) The amounts of p‐VEGFR‐1 and p‐VEGFR‐2 determined in three independent experiments of (A) were quantified and are represented as a bar diagram. The levels of p‐VEGFR‐1 and p‐VEGFR‐2 in recombinant canstatin‐ and rhVEGF‐A‐untreated cells were established as 100%. Data are presented as mean ± SD of three independent experiments (*P < 0.05).